Business Strategy & Product Development - Veracyte is expanding geographically with IVD products to address patient needs outside the US, with development on track for completion by the end of 2026[20, 21] - NIGHTINGALE enrollment is on track for completion in Q3, targeting 2,400 individuals to demonstrate clinical utility for the nasal swab test for lung cancer risk assessment[22] - The company plans further penetration and share gains, along with launches of MIBC MRD in 1H 2026 and Prosigna LDT2 in mid-2026, with additional MRD platform launches planned[34] Financial Performance (Q2 2025) - GAAP cost of testing revenue reached $32407 thousand[38] - GAAP gross profit was $89769 thousand, with a GAAP gross margin of 690%[38] - GAAP research and development expenses were $16264 thousand[40] - GAAP sales and marketing expenses amounted to $25316 thousand[40] - GAAP general and administrative expenses totaled $32331 thousand[40] - Adjusted EBITDA reached $35776 thousand, representing 275% of revenue[43] - GAAP net loss was $980 thousand, or -08% of revenue[43]